CSL Limited (CSLLY)
OTCMKTS · Delayed Price · Currency is USD
53.69
+0.69 (1.30%)
At close: Feb 18, 2026
CSL Limited Revenue
CSL Limited had revenue of $8.33B in the half year ending December 31, 2025, with 3.46% growth. This brings the company's revenue in the last twelve months to $15.41B, up 1.16% year-over-year. In the fiscal year ending June 30, 2025, CSL Limited had annual revenue of $15.56B with 5.12% growth.
Revenue (ttm)
15.41B
Revenue Growth
+1.16%
P/S Ratio
3.38
Revenue / Employee
515.22K
Employees
29,904
Market Cap
52.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 15.56B | 758.00M | 5.12% |
| Jun 30, 2024 | 14.80B | 1.49B | 11.19% |
| Jun 30, 2023 | 13.31B | 2.75B | 26.02% |
| Jun 30, 2022 | 10.56B | 252.00M | 2.44% |
| Jun 30, 2021 | 10.31B | 1.16B | 12.67% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| ZIVO Bioscience | 209.03K |
| Arch Biopartners | 198.11K |
CSL Limited News
- 10 hours ago - Eli Lilly's Landmark Trial Shows Major Psoriasis-Obesity Breakthrough With Taltz-Zepbound Combo - Benzinga
- 8 days ago - Half Year 2026 CSL Ltd Earnings Presentation Transcript - GuruFocus
- 8 days ago - CSL Limited (CSLLY) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 8 days ago - CSL Limited (CSLLY) Discusses Leadership Transition and Appointment of Interim CEO Transcript - Seeking Alpha
- 21 days ago - CSL Limited: Upside Potential Is Strong From These Levels But I Remain Cautious - Seeking Alpha
- 22 days ago - Deutsche Bank Appointed as Successor Depositary Bank for the American Depositary Receipt Program of CSL Limited - Business Wire
- 2 months ago - Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years - PRNewsWire
- 3 months ago - CSL Limited (CSLLY) Commits $1.5B to Expand U.S. Operations - GuruFocus